- Fecal Incontinence
Release Date: July 26, 2017 Expiration Date: July 26, 2018
This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with irritable bowel syndrome with constipation (IBS-C).
After completing this program, participants should be better able to:
Describe the burden of IBS-C and chronic idiopathic constipation (CIC) on patients and the healthcare system
Describe the evidence base regarding the efficacy and safety of conventional and newer therapies for IBS-C and CIC
Differentiate among newer therapies for IBS-C and CIC with regard to pharmacology, efficacy, safety, and tolerability
Learner Assurance Statement
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Gi Health Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.25 contact hours may be earned for successful completion of this activity.
Disclosure of Conflicts of Interest:
All faculty and staff involved in the planning or presentation of continuing education activities provided by Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. John Bayliss, VP, Business Development, Annenberg Center, spouse is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and Gi Health Foundation have no relationships to disclose.
Americans With Disabilities Act:
The event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact us prior to the event at 1-877-782-4532.
Accredited by the Annenberg Center for Health Sciences at Eisenhower
Provided by Gi Health Foundation
This program is not affiliated with Digestive Disease Week®. Supported by educational grants from Allergan, Inc., Commonwealth Diagnostics International, Inc., Ironwood Pharmaceuticals, Inc., and Synergy Pharmaceuticals.
For more information, email us at info@GiHealthFoundation.org, or call 1-877-782-4532.
University of Newcastle Callaghan, Australia
Northwestern University Feinberg School of Medicine Chicago, Illinois
University of Michigan Health System Ann Arbor, Michigan
John D. Dingell VA Medical Center Detroit, Michigan
Review of IBS-C and CIC pathophysiology, pharmacology of guanylate cyclase-C agonists and CIC-2 channel activators, epidemiology, key factors driving patients to seek care, and factors affecting treatment satisfaction
Review of evidence regarding the efficacy of current and emerging treatment options on global and individual IBS symptoms, safety/tolerability, and practical use in the clinic
Review of evidence regarding the efficacy of current and emerging treatment options on global and individual symptoms, safety/tolerability, and practical use in the clinic
Panel Discussion/Extended Q&A
Nicholas J. Talley, MD, is currently pro vice-chancellor of Global Research at the University of Newcastle, Australia. He is an expert clinician, educator, and researcher, with extensive experience as a leader in the medical and university sectors. He previously served as pro vice-chancellor (and dean) of the Faculty of Health and Medicine at the University of Newcastle from 2010 to 2015, and was seconded as deputy vice-chancellor of research (acting) at the University of Newcastle from June 2013 to March 2014.
Professor Talley has published over 1,000 original and review articles in peer-reviewed literature, and is considered one of the world’s most influential clinician-researchers (H index 116, Scopus). He is also a leading medical educator and the author of the highly regarded textbooks Clinical Examination and Examination Medicine. In June 2014, Professor Talley was inaugurated as one of the first 15 fellows of the Australian Academy of Health and Medical Sciences (FAHMS) and was elected to the Academy Council Executive.
In 2016, Professor Talley accepted a role as editor-in-chief of the Medical Journal of Australia, after stepping down from his role as co-editor-in-chief of Alimentary Pharmacology and Therapeutics after six years. He has completed two three-year terms (the maximum permitted) as co-editor-in-chief of the American Journal of Gastroenterology (with 12 years of consecutive international editing experience to date). These journals thrived under his leadership, and he substantially increased their impact (and impact factor) and readership. Professor Talley also serves on a number of prominent boards and is a section editor for UpToDate, a management tool widely used by clinicians globally.
Professor Talley was formerly chair of the Department of Internal Medicine at the Mayo Clinic in Jacksonville, Florida, where he was professor of medicine and professor of epidemiology. He was also the Foundation Professor of Medicine at the University of Sydney, Nepean Clinical School, for nearly a decade.
Professor Talley is a senior staff specialist and gastroenterologist at John Hunter Hospital and attends clinics and lists on a weekly basis. He holds adjunct research appointments as a professor at the Mayo Clinic, the University of North Carolina, and the Karolinska Institute. He is a fellow of the Royal Australasian College of Physicians (and past president), the Royal College of Physicians (both London and Edinburgh), the American College of Physicians, the American College of Gastroenterology, and the American Gastroenterological Association.
Other awards Professor Talley has received include the Rome Foundation Research Award, the American Gastroenterological Association (AGA) Distinguished Educator Award, the Newcastle Innovation Excellence in Innovation Award, the NSW Excellence in Biological Sciences (Cell and Molecular, Medical and Veterinary and Genetics) Premier's Prize, and the Distinguished Researcher Prize of the Gastroenterological Society of Australia.
Grants/Research Support: Abbott, Commonwealth Diagnostics International, Inc., Janssen Biotech, Inc., Pfizer Inc., Prometheus Laboratories Inc., Rome Foundation, Salix Pharmaceuticals, Inc.
Consultant/Speakers' Bureau/Editorial Board Involvement: Adelphi Values (functional dyspepsia working group to develop a symptom-based PRO instrument), Allergan plc (GI development programs), GI Therapies (noninvasive device company, consultant and options), Yuhan Corporation (IBS)
Darren M. Brenner, MD, AGAF, is an associate professor of medicine and surgery at Northwestern University Feinberg School of Medicine. He currently serves as director of the Gastrointestinal Physiology Laboratory and the Functional Bowel Program and as co-director of the Integrated Bowel Dysfunction Program. Dr. Brenner received his undergraduate degree from Washington University in St. Louis, his medical school training at the University of Chicago, and completed his residency and fellowship at the University of Michigan. His clinical and research pursuits focus predominantly on functional and motility disorders, and he is actively collaborating both nationally and internationally on studies in these areas. Dr. Brenner has also published extensively on these topics, and serves as a reviewer and associate editor for multiple GI peer-reviewed journals, including the American Journal of Gastroenterology, and has lectured regionally, nationally, and internationally on functional bowel disorders. He is a charter board member of the American Gastroenterological Association’s Academy of GI and Liver Educators, and also serves on the education, maintenance of certification, and publications committees of the American College of Gastroenterology. He is a fellow of the American Gastroenterological Association.
Grant/Research Support: AstraZeneca
Consultant/Speakers' Bureau: Allergan, Inc., AstraZeneca, Commonwealth Laboratories, Inc., Ironwood Pharmaceuticals, Inc., Procter & Gamble, QOL Medical, Salix Pharmaceuticals, Inc.
Advisory Board Membership: Allergan, Inc., AstraZeneca, Commonwealth Laboratories, Inc., Ironwood Pharmaceuticals, Inc., Procter & Gamble, QOL Medical, Salix Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc.
Editorial Board: American Journal of Gastroenterology (Associate Editor)
William D. Chey, MD, FACG, AGAF, FACP, RFF, received his BA from the University of Pennsylvania and his medical degree and training in internal medicine at Emory University School of Medicine. He completed his fellowship in gastroenterology at the University of Michigan in Ann Arbor, Michigan. Following his fellowship, Dr. Chey remained at the University of Michigan, where he is currently Timothy T. Nostrant Collegiate Professor of Gastroenterology, director of the GI Physiology Laboratory, co-director of the Michigan Bowel Control Program, and director of the GI Nutrition & Behavioral Wellness Program. In 2011, Dr. Chey was named an H. Marvin Pollard Institute Scholar at the University of Michigan, and was awarded a joint appointment in the Department of Nutritional Sciences in 2015.
Dr. Chey's research interests focus on the diagnosis and treatment of functional bowel disorders, acid-related disorders, and H. pylori infections. Funded by both federal and private sources, he is a medical innovator and holds four patents. Dr. Chey also co-founded My Total Health, a company that develops novel health information technology solutions for people with GI problems.
Dr. Chey has authored more than 350 manuscripts, including reviews, chapters, and books. He has served as co-editor-in-chief of the American Journal of Gastroenterology (2010-2015) and Clinical & Translational Gastroenterology (2011-2014). He is currently leading the update of the American College of Gastroenterology’s H. pylori practice guideline and participating in the creation of an AGA technical review on the diagnosis of IBS-D.
Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology (ACG), and joined the board of directors of the ACG Institute in 2014. He is also a member of the board of directors of the Rome Foundation and is on the editorial board for the Rome IV criteria.
Elected to "Best Doctors" since 2001 and "America's Top Doctors" since 2009, Dr. Chey was named as one of the "191 Gastroenterologists to Know" by Becker's ASC Review in 2015. In 2014, he was inducted into the Clinical Excellence Society of the Department of Medicine, received the Dean’s Outstanding Clinician Award, and was inducted into the League of Research Excellence at the University of Michigan. In 2015, he was inducted into the League of Clinical Excellence at the University of Michigan and received the Distinguished Clinician Award from the American Gastroenterological Association.
Consultant/Speakers' Bureau: Allergan, Inc., Astra-Zeneca, Biomerica, Inc., Ironwood Pharmaceuticals, Inc., Nestlé Institute of Health Sciences, Prometheus Laboratories Inc., QOL Medical, Ritter Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc.
Grants/Research Support: Ironwood Pharmaceuticals, Inc., Nestlé Institute of Health Sciences, Prometheus Laboratories Inc., QOL Medical, Synthetic Biologics, Inc., Vibrant Ltd., Zespri International Limited
Other Financial Material Support: My Total Health
Philip S. Schoenfeld, MD, MSEd, MSc (Epi), is chief of the Gastroenterology Section at the John D. Dingell VA Medical Center and adjunct professor of medicine at the University of Michigan School of Medicine. He is an expert in the management of irritable bowel syndrome (IBS), chronic constipation, gastroparesis, and pelvic floor disorders.
Dr. Schoenfeld completed his medical degree and his master’s degree in medical education at the University of Pennsylvania and his master’s degree in clinical epidemiology at McMaster University in Hamilton, Ontario, Canada.
His research, which is funded by the National Institutes of Health and the US Department of Veterans Affairs, focuses on the treatment of IBS and chronic constipation, the application of evidence-based medicine to the management of gastrointestinal disorders, and the optimization of colon cancer screening with colonoscopy.
Dr. Schoenfeld is the former editor of the Selected Summaries section of the journal Gastroenterology and the former associate editor (Colon section) of the American Journal of Gastroenterology, and has served on the editorial boards of the Journal of Clinical Gastroenterology, Alimentary Pharmacology and Therapeutics, and Gastroenterology & Hepatology. He is a co-author of the American Journal of Gastroenterology supplement “An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome” (2002) and its second edition (2009), the American Journal of Gastroenterology supplement “An Evidence-Based Position Statement on the Management of Chronic Constipation in North America” (2005), the American College of Gastroenterology Guidelines for Colorectal Cancer Screening (2008), and the American Society for Gastrointestinal Endoscopy/American College of Gastroenterology’s "Position Statement on Quality Indicators in the Performance of Colonoscopy" (in press).
Advisory Board: Allergan, Inc., Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Valeant Pharmaceuticals North America LLC
Speakers' Bureau: Allergan, Inc., Ironwood Pharmaceuticals, Inc.
© Copyright 2013-2023 GI Health Foundation. All rights reserved.